EGFR and head and neck squamous cell carcinoma: Although the EGFR antibody cetuximab is generally used in combination with radiation in HPV− HNSCC where cytotoxic chemotherapy is not the best option due to comorbidities, our data suggests that cetuximab in combination with radiotherapy or chemotherapy may be used to preempt or treat recurrent HPV+ HNSCC.